NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
71335-2122-06 | 71335-2122 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 3, 2024 | In Use | |
55700-0203-30 | 55700-0203 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 16, 2015 | Sep 30, 2025 | In Use |
00517-0440-01 | 00517-0440 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Mar 1, 2020 | In Use | ||
55513-0053-04 | 55513-0053 | Darbepoetin alfa | Aranesp | 150.0 ug/.75mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
80425-0227-01 | 80425-0227 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 11, 2023 | In Use | |
47335-0891-74 | 47335-0891 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
68083-0113-01 | 68083-0113 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 25, 2009 | In Use | |
70771-1348-05 | 70771-1348 | methylprednisolone | methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
55289-0373-72 | 55289-0373 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 29, 2015 | Aug 1, 2019 | In Use |
72189-0430-21 | 72189-0430 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 3, 2023 | In Use | |
71335-1516-01 | 71335-1516 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 20, 2020 | In Use | |
71335-2181-03 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct 25, 2022 | In Use | ||
63187-0513-30 | 63187-0513 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 1, 2018 | In Use | |
61919-0342-05 | 61919-0342 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 7, 2019 | In Use | |
43547-0258-01 | 43547-0258 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Jun 1, 2010 | Jul 1, 2018 | In Use |
00781-2322-46 | 00781-2322 | Aprepitant | Aprepitant | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
70860-0220-02 | 70860-0220 | Thiotepa | Thiotepa | 15.0 mg/1.5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Oct 15, 2022 | In Use | |
00641-6174-10 | 00641-6174 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Apr 4, 2005 | In Use | ||
68083-0142-01 | 68083-0142 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 5, 2018 | In Use | ||
63850-0129-03 | 63850-0129 | Everolimus | Everolimus | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 30, 2025 | In Use | |
59746-0782-30 | 59746-0782 | Prednisone | Prednisone | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 1, 2022 | May 1, 2026 | In Use |
54868-2522-01 | 54868-2522 | Filgrastim | Neupogen | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous | Jun 8, 1994 | In Use | |
55390-0391-10 | 55390-0391 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 40.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Mar 19, 2012 | In Use | |
51862-0086-51 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Mar 31, 2019 | In Use |
50242-0064-01 | 50242-0064 | Erlotinib Hydrochloride | Tarceva | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2005 | In Use |
Found 11765 results — Export these results